Replies to post #13972 on NanoLogix Inc (NNLX)

[medical veteran]

DP- You are entitled to your opinions and your comments are welcomed. You and everyone else is entitled to express your feelings and stock opinions.

[Omar8]

DP......



"....bad mouthing Nanologix for years."


Just read the past releases and how they have played out...the one who basically bad mouth themselves is their own releases.

No one could reasonable "bad mouth" a company that has done significant achievements and make plenty of money for their shareholders. Years of awesome releases to only be where we are now ? That doesn't deserve to be talked about ? Why you defend this specualtive company like it's more than that is interesting, do you know the CEO, friends with him ? If there is no attachment why so sensitive ?

[Omar8]

DP.........




"Finding a company with huge upside is challenging. Taking a company with huge upside to success is
more difficult......




Difficult ? Seems they were moving along here phase one done, then what ? They abandon something and moved onto something else ? I guess that would make success difficult when doing that kind of stuff.



"Dec. 16, 2019

NanoLogix Update on Phase One PreTest Development

NanoLogix is pleased to provide an update on the development of a Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.

[Omar8]

DP......



"......blaming CEO and bad mouthing Nanologix for years."


Does anyone believe if the company HAD captured a significant prcentage of the annual multibillion dollar market the PPS be where it is today ? Notice this was 12 years ago....


So I believe someone should be criticized !



"NanoLogix, Inc. Begins Construction of Production Facility for Medical Test Kits

Published: Apr 21, 2009

HUBBARD, Ohio, April 21 /PRNewswire-FirstCall/ -- NanoLogix, Inc. -- NanoLogix Inc. has begun construction on a 2,800 square foot manufacturing facility at its headquarters in Hubbard, Ohio. It will contain a production cleanroom, cold-storage vault, and shipping and receiving area to be used in the fabrication of BNP(TM) Ultra-Fast test kits.

The revolutionary new BNP(TM) kits provide accelerated detection of bacteria and pathogens -- 100 to 600% faster than conventional Petri plate testing. They will have broad applications in Homeland Security, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing.

One of the foremost bio-defense and biomedical research centers in the U.S. recently found in its tests that the BNP(TM) provided results up to four times faster than current Petri plate methods. Using the BNP(TM) they were able to view anthrax cultures in one-quarter of the time, and bubonic plague (Black Death) cultures in half of the time possible with the best traditional methods. The study appears in the current online issue of Letters in Applied Microbiology. Link to study:

http://nanologix.com/downloads/NNLX_resource_3.pdf

The new facility will replace the company's current limited-production operation at its research and development laboratory in Cincinnati, boosting production capability to thousands of BNP(TM) kits per day. This provides the opportunity for expanded R&D of other NanoLogix products at the Cincinnati lab.

The BNP(TM) kit is based on NanoLogix's revolutionary sandwiched-membrane Petri technology. The company believes the BNP(TM) has a high potential of capturing a significant percentage of the annual multi-billion dollar Petri plate market in both the United States and internationally.

NanoLogix CEO Bret Barnhizer stated: "With the BNP(TM) kits, we believe we are on our way to establishing a new 'gold Standard' for microorganism detection that will have a revolutionary effect on medical testing, diagnosis and treatment. This production facility will enable us to capitalize on our technology and provide product to those who are rapidly becoming aware of the BNP(TM) potential".

The test kits provide users the ability for faster detection of a long list of pathogens, including E-coli, Salmonella, Listeria, Enterobacter, Staphylococcus, Anthrax and Bubonic plague.

In addition to providing ultra-fast viewing of microorganisms normally cultured on standard Petri plates, the BNP(TM) kits can be used to assist in early detection of some of the most dangerous pathogens in the world, including those that pose significant potential threats for use as bio-weapons by terrorists.

The BNP(TM) production operation is expected to create a dozen jobs in the economically depressed Youngstown, Ohio, area, with more to follow as product demand increases...."